Pharmaceutical firm PowderJect is to start clinical trials of a vaccine to combat hepatitis B as part of its continuing alliance with GlaxoSmithKline.
The trial will involve 24 healthy volunteers and is designed to evaluate a range of different types of vaccination. Each volunteer will receive three doses of a DNA-based vaccine administered by the PowderJect needle-free system.
The study will then look at what sort of responses the vaccine creates, both among antibodies and in cells.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article